<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00624312</url>
  </required_header>
  <id_info>
    <org_study_id>07.0048</org_study_id>
    <nct_id>NCT00624312</nct_id>
  </id_info>
  <brief_title>Procrit Versus Placebo to Determine Efficacy in Pre-Operative Major Surgical Oncology Operations</brief_title>
  <official_title>A Prospective, Randomized, Double-Blinded Control Study of Procrit Versus Placebo to Determine Efficacy in Pre-Operative Patients Undergoing Major Surgical Oncology Operations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ortho Biotech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness of a two-dose regimen of Procrit&#xD;
      prior to a major surgical oncology operation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Anticipated">January 2010</completion_date>
  <primary_completion_date type="Anticipated">January 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients receiving transfusion.</measure>
    <time_frame>One Year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pre-operatively randomized to Procrit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Pre-operatively randomized to placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Procrit</intervention_name>
    <description>10 days prior to surgery - injection of 60,000 IU of Procrit&#xD;
Day of surgery - injection of 60,000 IU of Procrit</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Epoetin Alfa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>10 days prior to surgery - injection with 60,000 IU of placebo&#xD;
Day of surgery - injection with 60,000 IU of placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Undergoing a major surgical oncology procedure as defined below:&#xD;
&#xD;
               -  Pancreatectomy&#xD;
&#xD;
               -  Hepatectomy&#xD;
&#xD;
               -  Esophagectomy&#xD;
&#xD;
               -  Gastrectomy&#xD;
&#xD;
               -  Retroperitoneal Sarcoma Resection&#xD;
&#xD;
          -  18 years of age and older&#xD;
&#xD;
          -  Hemoglobin level of ≥ 10g/dL to &lt; 13g/dL, within 10 days of enrollment&#xD;
&#xD;
          -  If female of child-bearing potential, negative pregnancy test within 14 days prior to&#xD;
             surgery&#xD;
&#xD;
          -  If subject is a sexually active male or a sexually active female of child- bearing&#xD;
             potential, subject agrees to use a medically accepted form of contraception from the&#xD;
             time of enrollment to completion of all follow-up study visits&#xD;
&#xD;
          -  IRB-approved informed consent, signed by the subject or the subject's legally&#xD;
             authorized representative ≥ 18 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pre-operative hemoglobin level ≥ 13g/dL or &lt; 10g/dL&#xD;
&#xD;
          -  Uncontrolled hypertension (defined as a systolic pressure ≥ 160 and/or a diastolic&#xD;
             pressure ≥ 110)&#xD;
&#xD;
          -  History of allergy to Procrit®&#xD;
&#xD;
          -  Known hypersensitivity to mammalian cell-derived products or human albumin&#xD;
&#xD;
          -  History of spontaneous venous thrombotic vascular events&#xD;
&#xD;
          -  Anemia due to factors other than cancer,(e.g. iron deficiency, B12 deficiency)&#xD;
&#xD;
          -  History of (within 12 months) deep venous thrombosis (DVT), pulmonary embolus (PE), or&#xD;
             other venous thrombotic events. Prior superficial thrombophlebitis is not an exclusion&#xD;
             criterion&#xD;
&#xD;
          -  History of (within 6 months) uncontrolled cardiac arrhythmias, cerebrovascular&#xD;
             accident (CVA), transient ischemic attack (TIA), acute coronary syndrome (ACS), or&#xD;
             other arterial thrombosis. ACS includes Unstable Angina, Q wave Myocardial Infarction&#xD;
             (QwMI), and non-Q wave myocardial infarction (NQMI)&#xD;
&#xD;
          -  Currently receiving therapeutic or prophylactic anticoagulants for conditions other&#xD;
             than planned surgery. The only exceptions are low dose aspirin (≤ 325 mg/day) or low&#xD;
             dose anticoagulant to maintain patency of intravenous (IV) lines&#xD;
&#xD;
          -  Patient is a candidate for autologous blood transfusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Martin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Louisville</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>February 15, 2008</study_first_submitted>
  <study_first_submitted_qc>February 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2008</study_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Louisville</investigator_affiliation>
    <investigator_full_name>Robert C. Martin</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Procrit</keyword>
  <keyword>Erythropoietin</keyword>
  <keyword>Patients undergoing major surgical oncology operations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

